Merrimack Pharmaceuticals, Inc. (MACK)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
| Previous close | 14.73 |
| Open | 14.73 |
| Bid | 14.70 x 200 |
| Ask | 14.75 x 200 |
| Day's range | 14.72 - 14.77 |
| 52-week range | 11.53 - 15.89 |
| Volume | |
| Avg. volume | 130,246 |
| Market cap | 214.053M |
| Beta (5Y monthly) | 1.43 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.08 |
| Earnings date | 02 May 2024 - 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 13 Dec 2019 |
| 1y target est | N/A |
Business WireMerrimack Receives $225 Million Milestone Payment from Ipsen
CAMBRIDGE, Mass., March 27, 2024--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") today announced that it has received a $225 million payment which was due from Ipsen, S.A. as a result of its receipt of approval from the U.S. Food and Drug Administration, or FDA, to market ONIVYDE as a first-line treatment of metastatic adenocarcinoma on the pancreas.
Business WireMerrimack Reports Full Year 2023 Financial Results
CAMBRIDGE, Mass., March 07, 2024--Merrimack Reports Full Year 2023 Financial Results
Simply Wall St.Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) is definitely on the radar of hedge funds investors who own 35% of the company
Key Insights Significantly high institutional ownership implies Merrimack Pharmaceuticals' stock price is sensitive to...
© 2024 Yahoo. All rights reserved.